文献速递放射性药物与辐射防护肿瘤 PET/CT

[89Zr]Zr-oxine标记自体白细胞的首个人体剂量学与生物分布PET/CT研究

First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-10-02

前瞻性首个人体临床试验纳入4名健康成年女性(37-53岁),给予10.9±2.9 MBq [89Zr]Zr-oxine标记的自体白细胞,在0、4、24、48、72小时行全身PET/CT。给药耐受良好,脾脏吸收剂量系数最高(3.52±1.38 mGy/MBq),有效剂量系数为0.92±0.06 mSv/MBq,低于基于[111In]In-oxine标记白细胞的预测值1.14 mSv/MBq(P=0.006)。

要点

  • 4名健康女性受试者给药耐受良好,未见安全性问题报告。
  • 脾脏平均吸收剂量系数最高,为3.52±1.38 mGy/MBq。
  • 有效剂量系数0.92±0.06 mSv/MBq,低于[111In]In-oxine预测值。

核心结论

  • [89Zr]Zr-oxine标记白细胞在健康人体中安全且剂量学表现良好,支持其进一步用于自体白细胞PET显像。

研究设计与样本

  • 前瞻性首个人体临床试验纳入4名健康成年女性(年龄37-53岁),给予10.9±2.9 MBq [89Zr]Zr-oxine标记的自体白细胞,于0、4、24、48、72小时行全身PET/CT,用OLINDA 2.1估算剂量。

主要发现

  • 所有受试者给药耐受良好。
  • 平均吸收剂量系数最高的器官为脾脏3.52±1.38 mGy/MBq、肝脏2.1±0.45 mGy/MBq、肾上腺1.62±0.24 mGy/MBq、子宫1.48±0.98 mGy/MBq、肾脏1.36±0.12 mGy/MBq。
  • 平均有效剂量系数为0.92±0.06 mSv/MBq。
  • 该有效剂量系数数值上低于基于[111In]In-oxine标记白细胞在成年女性分布的预测值1.14 mSv/MBq(P=0.006,单样本t检验)。
  • [89Zr]Zr-oxine标记白细胞可实现白细胞分布及时间动力学的可视化。

关键数值与推荐

  • 脾脏平均吸收剂量系数3.52±1.38 mGy/MBq为所报告器官中最高。
  • 平均有效剂量系数0.92±0.06 mSv/MBq,低于预测值1.14 mSv/MBq(P=0.006)。

临床怎么用

  • 该首个人体数据支持在临床与研究场景中进一步用[89Zr]Zr-oxine标记自体白细胞行PET显像。

局限性

  • 样本量仅4名健康成年女性,年龄37-53岁,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cell tracking with zirconium-89 PET has the potential for widespread clinical and research applications, including imaging infection and inflammation and tracking cell-based therapies. This prospective first-in-human clinical trial assessed the dosimetry and safety profile of [89Zr]Zr-oxine-labeled autologous leukocytes in healthy female participants. METHODS: Four healthy adult female participants (ages 37-53) received 10.9 ± 2.9 MBq of [89Zr]Zr-oxine-labeled autologous leukocytes and underwent whole-body PET/CT imaging at five time points (0, 4, 24, 48, and 72 h). Regions of interest were automatically segmented on CT using a machine learning-based approach and manually refined. Time-integrated activity coefficients were calculated using Simpson's rule, with physical decay assumed beyond the final time point. Mean absorbed-dose and effective-dose coefficients were estimated using OLINDA 2.1. RESULTS: Administration was well-tolerated among all participants. The highest mean absorbed-dose coefficients (mGy/MBq) with standard deviation were observed in the spleen (3.52 ± 1.38), liver (2.1 ± 0.45), adrenals (1.62 ± 0.24), uterus (1.48 ± 0.98), and kidneys (1.36 ± 0.12). The mean effective-dose coefficient was 0.92 ± 0.06 mSv/MBq, numerically lower than the predicted value of 1.14 mSv/MBq based on the distribution of [111In]In-oxine-labeled leukocytes in adult females (P = 0.006, one-sample t-test). The use of [89Zr]Zr-oxine-labeled leukocytes enabled the visualization of leukocyte distribution and temporal dynamics. CONCLUSION: This study demonstrates the safety and favorable dosimetry of [89Zr]Zr-oxine-labeled leukocytes in healthy humans. These results support the further use of this approach for imaging autologous leukocytes using PET in a range of clinical and research settings. TRIAL REGISTRATION: ClinicalTrials.gov NCT03807973. Registered January 16, 2019.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gultekin K, Bartels JL, Cardenas CE, et al. First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 42825819. doi:10.1007/s00259-026-08158-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。